GeneDx Holdings Corp. (WGS) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 34 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Mon, Aug 3, 2026after close 34 8-K
Q1 FY2026Mon, May 4, 2026after close 34 8-K
Q4 FY2025Mon, Feb 23, 2026before open 54 8-K
Q3 FY2025Tue, Oct 28, 2025before open 28 8-K
Q2 FY2025Tue, Jul 29, 2025before open 29 8-K
Q1 FY2025Wed, Apr 30, 2025before open 30 8-K
Q4 FY2024Tue, Feb 18, 2025before open 49 8-K

What they guided beta

Q3 FY2026 "Reiterating full year 2026 revenue guidance of $475 to $490 million" exhibit
Read from the sentence: revenue $475 million to $490 million, FY2026
Q3 FY2026 "GeneDx 2026 Guidance GeneDx has updated its 2026 guidance and has provided guidance for the fourth quarter of 2026." exhibit
Q3 FY2026 "Management expects GeneDx to deliver: Metric Full Year 2026 Previous Guidance Full Year 2026 Updated Guidance Fourth Quarter 2026 Guidance Revenue $475 to $490 million $475 to $490 million $135 million Exome and genome volume At least 30% growth At least 28% growth 34,500 tests Exome and genome revenue At least 20% growth At least 17% growth $121 million Adjusted gross margin Approximately 70% Approximately 71% At least 71% Adjusted net income Positive Approximately $12 million Approximately $12 million Third Quarter 2026 and Recent Business Highlights Strategic Expansion and Market Leadership" exhibit
Q2 FY2026 "Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30%" exhibit
Q2 FY2026 "GeneDx 2026 Guidance GeneDx has reaffirmed its full year 2026 guidance and has provided guidance for the third quarter of 2026." exhibit
Q2 FY2026 "Management expects GeneDx to deliver: Metric Full Year 2026 Guidance Third Quarter 2026 Guidance Revenue $475 to $490 million $122 to $124 million Exome and genome volume At least 30% growth 33,200 tests Exome and genome revenue At least 20% growth $110 to $112 million Adjusted gross margin Approximately 70% Approximately 70% Adjusted net income Positive Approximately $2 million Second Quarter 2026 and Recent Business Highlights Strategic Expansion and Market Leadership" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/WGS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/WGS

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

WGS earnings date badge

HTML

<a href="https://veritasdata.dev/company/WGS/"><img src="https://veritasdata.dev/embed/WGS.svg" alt="WGS earnings date" width="240" height="56"></a>

Markdown

[![WGS earnings date](https://veritasdata.dev/embed/WGS.svg)](https://veritasdata.dev/company/WGS/)

Script

<script async src="https://veritasdata.dev/embed/WGS.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/WGS"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.